Posted by Michael Wonder on 19 Jun 2019
FDA grants fast track designation for Torque's first deep-primed T cell cancer immunotherapy program, TRQ-1501
18 June 2019 - Torque announced today that the U.S. FDA granted fast track designation for Torque's first Deep-Primed T cell immunotherapy program, TRQ-1501.
The fast track designation is for the treatment of relapsed or refractory solid tumours and lymphomas that express any of five tumour-associated antigens (PRAME, WT-1, SSX2, Survivin, and NY-ESO-1).
Torque is currently conducting a Phase 1/2 clinical trial of TRQ-1501 for this indication.
